These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 19534792)

  • 21. Accelerator mass spectrometry for quantitative in vivo tracing.
    Vogel JS
    Biotechniques; 2005 Jun; Suppl():25-9. PubMed ID: 16528913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data.
    Garner RC
    Bioanalysis; 2010 Mar; 2(3):429-40. PubMed ID: 21083253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accelerator mass spectrometry analyses of environmental radionuclides: sensitivity, precision and standardisation.
    Hotchkis M; Fink D; Tuniz C; Vogt S
    Appl Radiat Isot; 2000 Jul; 53(1-2):31-7. PubMed ID: 10879834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Accelerator mass spectrometry analysis of background (14)C-concentrations in human blood: aiming at reference data for further microdosing studies.
    Minamimoto R; Hamabe Y; Miyaoka T; Hara T; Yoshida K; Oka T; Inoue T
    Ann Nucl Med; 2008 Dec; 22(10):883-9. PubMed ID: 19142707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitating isotopic molecular labels with accelerator mass spectrometry.
    Vogel JS; Love AH
    Methods Enzymol; 2005; 402():402-22. PubMed ID: 16401517
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biological/biomedical accelerator mass spectrometry targets. 1. optimizing the CO2 reduction step using zinc dust.
    Kim SH; Kelly PB; Clifford AJ
    Anal Chem; 2008 Oct; 80(20):7651-60. PubMed ID: 18785761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Accelerator Mass Spectrometry (AMS) in Radioecology.
    García-León M
    J Environ Radioact; 2018 Jun; 186():116-123. PubMed ID: 28882579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of accelerator mass spectrometry (AMS) for high-sensitivity measurements of 14CO2 in long-term studies of fat metabolism.
    Stenström K; Leide-Svegborn S; Erlandsson B; Hellborg R; Mattsson S; Nilsson LE; Nosslin B; Skog G; Wiebert A
    Appl Radiat Isot; 1996 Apr; 47(4):417-22. PubMed ID: 8624508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DNA isolation and sample preparation for quantification of adduct levels by accelerator mass spectrometry.
    Dingley KH; Ubick EA; Vogel JS; Haack KW
    Methods Mol Biol; 2005; 291():21-7. PubMed ID: 15502208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microdose study of 14C-acetaminophen with accelerator mass spectrometry to examine pharmacokinetics of parent drug and metabolites in healthy subjects.
    Tozuka Z; Kusuhara H; Nozawa K; Hamabe Y; Ikushima I; Ikeda T; Sugiyama Y
    Clin Pharmacol Ther; 2010 Dec; 88(6):824-30. PubMed ID: 21048707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioanalytical applications of accelerator mass spectrometry for pharmaceutical research.
    Turteltaub KW; Vogel JS
    Curr Pharm Des; 2000 Jul; 6(10):991-1007. PubMed ID: 10828298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Accelerator mass spectrometry (AMS): recent experience of its use in a clinical study and the potential future of the technique.
    Young G; Ellis W; Ayrton J; Hussey E; Adamkiewicz B
    Xenobiotica; 2001; 31(8-9):619-32. PubMed ID: 11569529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Application of liquid chromatography-accelerator mass spectrometry (LC-AMS) to evaluate the metabolic profiles of a drug candidate in human urine and plasma.
    Prakash C; Shaffer CL; Tremaine LM; Liberman RG; Skipper PL; Flarakos J; Tannenbaum SR
    Drug Metab Lett; 2007 Aug; 1(3):226-31. PubMed ID: 19356047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Accelerating clinical insights: how to use accelerator mass spectrometry to make better early development decisions.
    Seymour M
    Altern Lab Anim; 2010 Dec; 38 Suppl 1():15-20. PubMed ID: 21275478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Accelerator MS: its role as a frontline bioanalytical technique.
    Seymour MA
    Bioanalysis; 2011 Dec; 3(24):2817-23. PubMed ID: 22185281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microdosing studies using accelerated mass spectrometry as exploratory investigational new drug trials.
    Bae SK; Shon JH
    Arch Pharm Res; 2011 Nov; 34(11):1789-98. PubMed ID: 22139681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of an intravenous microdose of 14C-labeled drug and accelerator mass spectrometry to measure absolute oral bioavailability in dogs; cross-comparison of assay methods by accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
    Miyaji Y; Ishizuka T; Kawai K; Hamabe Y; Miyaoka T; Oh-hara T; Ikeda T; Kurihara A
    Drug Metab Pharmacokinet; 2009; 24(2):130-8. PubMed ID: 19430168
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accelerator mass spectrometry offers new opportunities for microdosing of peptide and protein pharmaceuticals.
    Salehpour M; Ekblom J; Sabetsky V; Håkansson K; Possnert G
    Rapid Commun Mass Spectrom; 2010 May; 24(10):1481-9. PubMed ID: 20411588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of accelerator mass spectrometry for studies in nutrition.
    Jackson GS; Weaver C; Elmore D
    Nutr Res Rev; 2001 Dec; 14(2):317-34. PubMed ID: 19087429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microdosing for early biokinetic studies in humans.
    Stenström K; Sydoff M; Mattsson S
    Radiat Prot Dosimetry; 2010; 139(1-3):348-52. PubMed ID: 20167793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.